SOURCE: Barrier Therapeutics, Inc.

October 01, 2007 07:30 ET

Barrier Therapeutics to Present at the Natixis Bleichroeder Hidden Gems Conference

PRINCETON, NJ--(Marketwire - October 1, 2007) - Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced that Mr. Al Altomari, Chief Operating Officer, and Ms. Anne VanLent, Executive Vice President and Chief Financial Officer, will participate in the Natixis Bleichroeder Hidden Gems Conference to be held at the Carlton Hotel in New York on October 8 - October 9, 2007. Barrier Therapeutics is scheduled to present on Monday, October 8, at 10:30 a.m. EDT.

The presentation will be available via a live webcast and can be accessed through the Investor Relations section of Barrier Therapeutics' corporate website at: www.barriertherapeutics.com. An archive of the presentation will be available for replay for 90 days.

About Barrier Therapeutics

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion® (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    EVP & CFO
    (609) 945-1202

    Lazar Partners Ltd.
    Gregory Gin
    Investor Relations
    (212) 867-1762